NovoCure (NVCR) Capital Expenditures Growth (3y) (2017 - 2026)
NovoCure (NVCR) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 9.52% |
| 10 | NovoCure | 1.99 Bn | 1.55 Bn | 142.48 Mn | -0.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.07% |
| Mar 31, 2026 | -5.41% |
| Dec 31, 2025 | -8.69% |
| Sep 30, 2025 | -0.28% |
| Jun 30, 2025 | 9.92% |
| Mar 31, 2025 | 27.72% |
| Dec 31, 2024 | -14.43% |
| Sep 30, 2024 | 47.98% |
| Jun 30, 2024 | 63.52% |
| Mar 31, 2024 | 43.58% |
| Dec 31, 2023 | 5.80% |
| Sep 30, 2023 | 11.92% |
| Jun 30, 2023 | 27.87% |
| Mar 31, 2023 | 25.07% |
| Dec 31, 2022 | 28.16% |
| Sep 30, 2022 | 28.18% |
| Jun 30, 2022 | 19.89% |
| Mar 31, 2022 | 29.87% |
| Dec 31, 2021 | 99.67% |
| Sep 30, 2021 | 34.57% |